In 2019, an all-time high number of investigational new drug (IND) applications were submitted for gene therapy products in clinical research. Additionally, with coronavirus (SARS-CoV-2) and the disease it causes (COVID-19), vaccine research has been in the limelight for much of 2020. Even with SARS-CoV-2 is at the forefront of researchers’ minds, and many decisions surrounding SARS-CoV-2 are driven through research, gene therapy research is prevalent in oncology and rare diseases as well. While great strides have been made in genetic research, to continue, some remaining obstacles need to be addressed.
In an effort to begin conversations about these obstacles, Advarra presents its first virtual symposium, Gene Therapy Research in the Age of COVID-19: Study Startup Success for Infectious Disease, Oncology, and Rare Disease Research. This symposium will feature a virtual panel discussion on emerging issues in gene therapy research.
To learn more, read the full article on Advarra’s website.